[Basic fibroblast growth factor as a prognostic factor of medication efficacy by meanes of prostatic adenoma].
To determine prognostic factors of lower urinary tract symptoms progression because of prostatic adenoma (PA), we studied content of the basic fibroblast growth factor (bFGF) in blood serum of patients with PA in enzyme immunoassay. We also studied efficacy of 2-year combined treatment of PA patients with finasteride (inhibitor of 5alpha-reductase) in a dose 5 mg/day and tamsulosin (alpha-adrenoblocker) in a dose 0.4 mg/day regarding bFGF concentration in blood serum. We found that mean bFGF in the serum of PA patients is elevated in most cases varying in the range from 1.61 +/- 0.5 to 44.0 +/- 10.8 pg/ml. The combined treatment for 2 years significantly reduces points by IPSS, volume of residual urine, increases Qmax in patients with serum bFGF concentration under 4.2 pg/ml, while in patients with bFGF concentration above 5.9 pg/ml the above treatment failed. Thus, a bFGF concentration in the serum is a reliable prognostic factor of PA medication efficacy.
Boroian
R R
RR
D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage*; D000368:Aged; D000369:Aged, 80 and over; D004791:Enzyme Inhibitors / Q000008:administration & dosage*; D016222:Fibroblast Growth Factor 2 / Q000097:blood*; D018120:Finasteride / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011470:Prostatic Hyperplasia / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy*; D013449:Sulfonamides / Q000008:administration & dosage*; D000077409:Tamsulosin; D013997:Time Factors
D000317:Adrenergic alpha-Antagonists; D004791:Enzyme Inhibitors; D013449:Sulfonamides; D016222:Fibroblast Growth Factor 2; D018120:Finasteride; D000077409:Tamsulosin